Q4 FY24 Revenue: Gross revenue of INR 427 crores, 16.5% increase from INR. 367 crores in Q4’FY23.
EBITDA for Q4’FY24 surged by 182% to INR 52.62 crores from INR. 18.68 crores in the same quarter last year. For the full fiscal year, EBITDA more than doubled, achieving INR. 172.60 crores, up 101% from INR. 85.67 crores in FY23
Annual FY24 Revenue: INR 1704 crores, a notable 20% rise compared to INR 1424 crores in FY23.
PBT for Q4’FY24 was INR. 42.20 crores, a substantial increase of 279% from INR. 11.14 crores in Q4 FY23. Annually, PBT grew by 143% to INR. 135.42 crores from INR. 55.76 crores in FY23.
PAT for Q4’FY24 stood at INR. 28.74 crores, showing a 249% growth compared to INR. 8.24 crores in the same period last year. On an annual basis, PAT increased by 150% to INR. 96.62 crores from INR. 38.68 crores in FY23.
Earnings Per Share (EPS): Jumped from INR 0.77 to INR 1.88 for FY24, indicating a great start to the journey ahead.
Q3'FY24 Revenue at Rs. 449 crores is up by 28% on a y-o-y basis. 9M revenue of Rs. 1277 crores, is up 21%.
Domestic revenue for the Q3 at Rs. 271 crores is up by 27%. For the 9M period, at Rs. 829 Crores, revenue growth is at 30%
API total revenue at Rs. 253 Crores for Q3 is up by 20% on a y-o-y basis, whereas for a 9M period at Rs. 668 Crores
Revenues growth is at 10%. API Q3 exports at Rs. 176 Crores are up by 31% while Domestic Business is up only 1%.
Q3 revenue for the Formulation business at Rs. 65 crores is up by 40% whereas, for 9 months period, revenue growth is at 22% for Rs. 166 Crores
The medical devices business continues its high growth journey with 24% revenue growth in Q3 and a 37% jump in the 9M period.
Gut Reaching Probiotics – Revolutionary, Intebact
up18news.com
Morepen Laboratories consolidated net profit rises 243.20% in the March 2024 quarter
business-standard.com
Morepen Lab Standalone March 2024 Net Sales at Rs 392.60 crore, up 16.66% Y-o-Y
www.moneycontrol.com
Empowering Health. Everywhere
Morepen is dedicated to providing affordable, high-quality healthcare solutions through innovative pharmaceutical and medical technology products. We strive to make health accessible for all and achieve a global reach.
Excellence. Passion. Action. Innovation
Morepen is driven by a commitment to excellence in everything we do. Our three core values – Passion, Action, and Innovation – guide our actions. We prioritize delivering superior quality products, efficient distribution networks, and exceptional customer service. We are a passionate and results-oriented team, leveraging technology for continuous research and development. Our goal is to remain at the forefront of healthcare solutions.
Annual Return
Annual Secretarial Compliance Report
Newspaper Advertisements